Long-term safety and effectiveness of eculizumab in patients with AQP4+neuromyelitis optica spectrum disorder: 3 years of data from Japanese post-marketing surveillance

被引：0
|
作者：
Nakahara, Jin [1 ]
Nakashima, Ichiro [2 ]
Yokote, Hiroaki [3 ]
Manabe, Yasuhiro [4 ]
Okamura, Kazumi [5 ]
Hasegawa, Kou [5 ]
Fujihara, Kazuo [6 ,7 ]
机构：
[1] Keio Univ, Dept Neurol, Sch Med, Tokyo, Japan
[2] Tohoku Med & Pharmaceut Univ, Div Neurol, Sendai, Japan
[3] Tokyo Metropolitan Komagome Hosp, Dept Neurol, Tokyo, Japan
[4] Natl Hosp Org Okayama Med Ctr, Dept Neurol, Okayama, Japan
[5] Alexion Pharma GK, Tokyo, Japan
[6] Fukushima Med Univ, Fukushima, Japan
[7] Southern TOHOKU Res Inst Neurosci STRINS, Koriyama, Japan
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P010/1870
引用
收藏
页码：144 / 144
页数：1
相关论文
共 50 条
  • [41] Long-term safety and effectiveness of stiripentol in patients with Dravet syndrome: Interim report of a post-marketing surveillance study in Japan
    Yamada, Miyuki
    Suzuki, Katsuyoshi
    Matsui, Daisuke
    Inoue, Yushi
    Ohtsuka, Yoko
    EPILEPSY RESEARCH, 2021, 170
  • [42] Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3,267 Japanese patients with rheumatoid arthritis
    Takeuchi, Tsutomu
    Kawai, Shinichi
    Yamamoto, Kazuhiko
    Harigai, Masayoshi
    Ishida, Kota
    Miyasaka, Nobuyuki
    MODERN RHEUMATOLOGY, 2014, 24 (01) : 8 - 16
  • [43] Long-term efficacy and safety of satralizumab in adults with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD): results from the Phase 3 SAkura studies
    Moghaddam, Shervin Gholizadeh
    Bennett, Jeffrey L.
    Fox, Edward
    Greenberg, Benjamin
    Weinshenker, Brian G.
    Traboulsee, Anthony
    Yeaman, Michael R.
    Blondeau, Kathleen
    Weber, Kristina
    Vodopivec, Ivana
    Levy, Michael
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [44] Long-term Efficacy and Safety of Satralizumab in Adults with AQP4-IgG-seropositive Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from the Phase 3 SAkura studies
    Bennett, J. L.
    Fox, E.
    Greenberg, B.
    Weinshenker, B. G.
    Traboulsee, A.
    Yeaman, M. R.
    Blondeau, K.
    Weber, K.
    Gholizadeh, S.
    Vodopivec, I.
    Levy, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 146 - 146
  • [45] Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance study
    Yabe, Daisuke
    Yamamoto, Fumiko
    Lund, Soren S.
    Okamura, Tomoo
    Kadowaki, Takashi
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (10) : 1303 - 1313
  • [46] Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance
    Ito, Tomohiro
    Naito, Yusuke
    Shimmoto, Naoki
    Ochiai, Kaori
    Hayashi, Naoyuki
    Okamura, Tomoo
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (03) : 363 - 371
  • [47] Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan
    Ikezoe, Takayuki
    Noji, Hideyoshi
    Ueda, Yasutaka
    Kanda, Yoshinobu
    Okamoto, Shinichiro
    Usuki, Kensuke
    Matsuda, Takahisa
    Akiyama, Hirozumi
    Shimono, Akihiko
    Yonemura, Yuji
    Kawaguchi, Tatsuya
    Chiba, Shigeru
    Kanakura, Yuzuru
    Nishimura, Jun-Ichi
    Ninomiya, Haruhiko
    Obara, Naoshi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 115 (04) : 470 - 480
  • [48] Long-term Safety of Satralizumab in Adults with Aquaporin-4-IgG-seropositive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from SAkuraMoon
    Weinshenker, Brian
    Yeaman, Michael R.
    de Seze, Jerome
    Patti, Francesco
    Vodopivec, Ivana
    Blondeau, Kathleen
    Klingelschmitt, Gaelle
    Marcillat, Carole
    Greenberg, Benjamin M.
    Gholizadeh, Shervin
    NEUROLOGY, 2023, 100 (17)
  • [49] Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan
    Takayuki Ikezoe
    Hideyoshi Noji
    Yasutaka Ueda
    Yoshinobu Kanda
    Shinichiro Okamoto
    Kensuke Usuki
    Takahisa Matsuda
    Hirozumi Akiyama
    Akihiko Shimono
    Yuji Yonemura
    Tatsuya Kawaguchi
    Shigeru Chiba
    Yuzuru Kanakura
    Jun‑ichi Nishimura
    Haruhiko Ninomiya
    Naoshi Obara
    International Journal of Hematology, 2022, 115 : 470 - 480
  • [50] Post-Marketing Surveillance of Fluvoxamine Maleate Used Long-Term in Patients with Social Anxiety Disorder in Japan
    Asakura S.
    Koyama T.
    Hosokai T.
    Kawano H.
    Kajii Y.
    Drugs - Real World Outcomes, 2014, 1 (1) : 7 - 19
12345